| Characteristic | Average time in days |
|---|---|
| Romania | 936 |
| Slovakia | 911 |
| Portugal | 910 |
| Croatia | 843 |
| Ireland | 801 |
| Czechia | 776 |
| Poland | 722 |
| France | 665 |
| Sweden | 651 |
| Greece | 649 |
| Latvia | 638 |
| Lithuania | 629 |
| Slovenia | 601 |
| Estonia | 592 |
| Belgium | 589 |
| Bulgaria | 585 |
| Spain | 579 |
| Norway | 572 |
| Hungary | 567 |
| Netherlands | 561 |
| Finland | 497 |
| Luxembourg | 495 |
| Italy | 453 |
| Cyprus | 436 |
| Turkey | 400 |
| Denmark | 387 |
| Austria | 356 |
| Scotland | 345 |
| Switzerland | 323 |
| England | 269 |
| Serbia | 216 |
| North Macedonia* | 213 |
| Germany | 124 |
| Iceland | - |
The chart is not accessible to screen readers. Please switch to the table view to access the data.
Loading statistic...
Download
Source
Sources
Release date
May 2026
More information
Region
Europe
Survey time period
2021 to 2024
Supplementary notes
Data collected is for drugs launched from 2021 to 2024. In most countries, availability equates to granting of access to the reimbursement list, except in DK, FI, NO, SE, where some hospital products are not covered by the general reimbursement scheme. The time to availability (formerly known as length of delay) is the days between EMA marketing authorization and the date of availability to patients.Â
* These countries did not complete a full dataset, and therefore, availability may be unrepresentative.
Citation formats
